In response to evolving regulatory expectations, the industry is moving toward integrated, risk-based, and transparent sterility assurance systems for the manufacture of sterile injectable products. CDMOs like GRAM are adapting by embedding continuous improvement, advanced technologies, and lifecycle considerations into their operations.

Jennifer Leale, Director QA & Regulatory Affairs at Grand River Aseptic Manufacturing shares insight on strategies for compliance and validation and evolving regulatory expectations beyond Annex 1.

Contract Pharma: How have compliance and validation expectations evolved based on interpretations from the FDA and other regulatory bodies?

Jennifer Leale: We are seeing regulatory agencies shift from “prove you followed the procedure” to “prove your process is designed and controlled to prevent contamination.” Increasingly, the expectation for manufacturers is to demonstrate process understanding and proactive risk control, rather than relying solely on environmental monitoring or final testing. The evolution is positive and adds collaboration at each step of the sterile filling process. With a focus on transparency, CDMOs are now expected to provide deeper insight into sterility assurance programs and contamination control, which is intuitive with newer filling technologies.

Current compliance and validation expectations include:

• Holistic contamination control strategies (CCS): Manufacturers must implement a facility-wide CCS covering facility design, equipment, personnel practices, materials flow, cleaning, environmental monitoring, and process controls. 
• Lifecycle process validation and continual verification: Regulators now expect validation programs to include ongoing process monitoring, trending, and lifecycle review, not just initial qualification.
• Integration of quality risk management and pharmaceutical quality systems: Risk assessments must justify facility design, process parameters, monitoring frequencies, and alternative approaches to standard requirements. 
• Greater focus on facility and equipment design: Technologies such as isolators are increasingly expected to minimize human intervention and contamination risk. 
• Heightened expectations for data integrity and transparency: Regulators expect CDMOs to provide sponsors and inspectors with full visibility into sterility assurance programs and contamination control measures.

Contract Pharma: What do CDMOs need to reevaluate to keep up with these regulatory expectations?

Jennifer Leale: CDMOs should take a deep look at their sterility assurance programs and contamination control strategies. Sponsor transparency is becoming increasingly important, as clients expect visibility into sterility assurance systems and contamination risk management. CDMOs must move from compliance-driven systems to integrated sterility assurance systems that are scientifically justified and continuously monitored. It is possible they need to reassess their entire sterility assurance framework to ensure it is integrated, documented, and risk-based rather than fragmented across individual SOPs. 

Areas requiring reevaluation include:

• Facility and process design: Use of barrier technologies (isolators/RABS), material and personnel flow, air handling and cleanroom classification, and automation to reduce manual interventions.
• Environmental monitoring programs: Alignment with risk-based monitoring locations, trending and statistical analysis, and integration with contamination investigations.
• Aseptic process validation: Media fill strategy and frequency, worst-case conditions and interventions, and personnel qualification programs.
• Quality risk management: Formal risk assessments supporting process controls, and linkage between risk assessments and monitoring strategy.
• Supplier and raw material controls: Bioburden and endotoxin control, supplier qualification, and incoming testing.
• Data integrity and quality oversight: Robust trending and management review, and integrated quality metrics and CAPA systems.

Contract Pharma: Has GRAM implemented changes that address the gap between previous GMP standards and the revised Annex 1?   If so, how?

Jennifer Leale: GRAM has taken a proactive approach to aligning its quality systems and sterile manufacturing operations with the expectations outlined in the revised Annex 1. These initiatives include:

• Implementation of a comprehensive Contamination Control Strategy (CCS): GRAM has developed a facility-wide CCS that integrates facility design, personnel practices, environmental monitoring, cleaning and disinfection programs, and process controls into a single sterility assurance framework.
• Enhanced aseptic process validation programs: The organization evaluated its media fill and aseptic simulation strategies to ensure they represent worst-case process conditions and critical interventions.
• Risk-based environmental monitoring and trending: Environmental monitoring, trending, and assessments were assessed to ensure monitoring locations and frequencies are scientifically justified.
• Expanded quality risk management integration: Risk assessments are more routinely used to support decisions related to facility changes, process improvements, and validation strategies.
• Technology and process improvements: Where possible, GRAM continues to evaluate opportunities to reduce operator intervention and strengthen sterility assurance through modern manufacturing technologies.

These initiatives help ensure GRAM’s sterile manufacturing operations align with both Annex 1 requirements and evolving global regulatory expectations.

Contract Pharma: How does GRAM constantly evolve when Annex 1 is not enough?

Jennifer Leale: Rather than treating Annex 1 as the ceiling for compliance, GRAM treats it as a foundation for building a modern sterility assurance program. While Annex 1 provides critical guidance for sterile manufacturing, GRAM recognizes that regulatory expectations continue to evolve. As a result, the organization maintains a culture of continuous quality improvement.

Our ongoing review beyond Annex 1 includes:

• Continuous monitoring of regulatory trends: FDA inspection trends, EMA and MHRA expectations, and PDA and ISPE industry guidance,
• Lifecycle quality system improvements: Periodic review of contamination control strategies, trending of environmental and process performance data, and continuous risk assessment updates.
• Investment in new technologies: Automation and barrier technologies.
• Cross-functional quality governance: Routine management review of sterility assurance performance.
• Proactive inspection readiness: Internal audits and mock inspections, and continuous improvement of data integrity and documentation practices.

Contract Pharma: What is GRAM’s strategy for compliance with current equipment? How does GRAM validate sterilization cycles for these systems?

• Pre-Use Post-Sterilization Integrity Testing (PUPSIT): GRAM performs PUPSIT on sterile filters prior to filling. In accordance with Annex 1 expectations, the integrity of sterilizing-grade filters is verified pre-use post-sterilization using non-destructive integrity testing methods. Standardized single-use systems for filtration streamline the process for on-the-floor personnel. In cases where PUPSIT is not technically feasible due to process constraints, GRAM implements a documented, science and risk-based justification supported by a formal risk assessment.
  
  
• Lyophilization: GRAM’s lyophilization equipment includes automation within an isolator. Annex 1 compliance was part of the equipment selection process, and automated loading and unloading is a capability of GRAM’s IMA Lyophilizer. All loading and unloading of vials takes place within a Grade A environment, which reduces the need for operator intervention or dealing with a HEPA cart. Additionally, the lyophilizer has multiple Pirani gauges that could be used to monitor the point of nucleation and may help develop or even improve the lyo cycle long term.
  
  
• Isolator technology: GRAM’s five filling lines all include isolator technology. Sterilization cycles for the isolators are completed using either vaporized or nebulized hydrogen peroxide decontamination. To develop the cycles, we leverage a close relationship with the isolator OEM, SKAN. Critical parameters such as the residual H202 concentration after aeration, the overall loading pattern, and assessment of worst-case positions with the isolator are identified prior to starting any recipe development work. Once the initial cycle is developed (with a sufficient safety margin), GRAM begins in-house qualification using max load patterns and biological indicators (BIs) throughout the isolator.